Trials / Completed
CompletedNCT02669940
Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation - An Observational, Multi-Center Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 158 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study seeks to assess the effectiveness, patient reported outcomes, work productivity and healthcare resource utilization of the interferon-free regimen of paritaprevir /ritonavir (r) - ombitasvir, ± dasabuvir ± ribavirin (RBV) in participants with chronic hepatitis C in a real life setting across clinical practice populations.
Conditions
Timeline
- Start date
- 2016-04-15
- Primary completion
- 2017-07-04
- Completion
- 2017-07-04
- First posted
- 2016-02-01
- Last updated
- 2018-11-14
- Results posted
- 2018-11-14
Source: ClinicalTrials.gov record NCT02669940. Inclusion in this directory is not an endorsement.